GGHC
MLTX icon

Gilder Gagnon Howe & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,959
Closed -$853K – 264
2023
Q3 		$853K Sell
14,959
-88
-0.6% -$4.86K 0.01% 217
2023
Q2 		$767K Buy
+15,047
New +$405K 0.01% 237

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's MLTX Position: Q4 2023 in Review

Gilder Gagnon Howe & Co sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 14,959 shares — an estimated $853K sold.

Gilder Gagnon Howe & Co first reported a position in MLTX in Q2 2023 and held it in 2 quarters. The position peaked at $853K in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • Gilder Gagnon Howe & Co reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 14,959 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $853K.
  • Gilder Gagnon Howe & Co first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's MoonLake Immunotherapeutics position peaked at $853K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2023, filed 14 Feb 2024.